Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W2HD
|
|||
Former ID |
DNC014900
|
|||
Drug Name |
Mogamulizumab
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Mycosis fungoides [ICD-11: 2B01; ICD-10: C84.0] | Approved | [1] | |
Sezary syndrome [ICD-11: 2B02; ICD-10: C84.1] | Approved | [1] | ||
Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.8; ICD-9: 202.1, 202.2] | Phase 3 | [2], [3], [4] | ||
T-cell leukaemia [ICD-11: 2A90; ICD-10: C86] | Phase 2 | [2], [3], [4] | ||
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [2], [3] | ||
Company |
Kyowa Hakko Kirin
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | C-C chemokine receptor type 4 (CCR4) | Target Info | Inhibitor | [5] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Chemokine signaling pathway | ||||
Viral carcinogenesis | ||||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
Reactome | Chemokine receptors bind chemokines | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 5 | Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.